Skip to main content

Master of Public Health

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.

AUTHORS

Frey SE , Wald A , Edupuganti S , Jackson LA , Stapleton JT , Sahly HE , El-Kamary SS , Edwards K , Keyserling H , Winokur P , Keitel W , Hill H , Goll JB , Chaplin P , Belshe RB , , Anderson EL , Graham IL , Johnston C , Mulligan M , Rouphael N , Atmar R , Patel S , Chen W , Kotloff K , Creech CB , . Vaccine. 2015 7 1; ().

ABSTRACT

Modified vaccinia Ankara (MVA) is being developed as a safer smallpox vaccine and is being placed in the US Strategic National Stockpile (SNS) as a liquid formulation for subcutaneous (SC) administration at a dose of 1×10(8) TCID50 in a volume of 0.5mL. This study compared the safety and immunogenicity of the standard formulation, dose and route with both a more stable, lyophilized formulation and with an antigen-sparing intradermal (ID) route of administration.

Modified vaccinia Ankara (MVA) is being developed as a safer smallpox vaccine and is being placed in the US Strategic National Stockpile (SNS) as a liquid formulation for subcutaneous (SC) administration at a dose of 1×10(8) TCID50 in a volume of 0.5mL. This study compared the safety and immunogenicity of the standard formulation, dose and route with both a more stable, lyophilized formulation and with an antigen-sparing intradermal (ID) route of administration.

Tags: